- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01256294
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
A Prospective, Multi-center, Open-label, Randomized, Two Period, Two Sequence, Crossover Study to Compare the Steady State Pharmacokinetics of Generic Tacrolimus (Sandoz) to Prograf in Stable Renal Transplant Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to participate and willing to give written informed consent and to comply with the study visits and restrictions.
- Patient who has received a primary or secondary kidney transplant
- Patient who is at least 6 months post transplant and on a stable dose of tacrolimus as defined by physician, one tacrolimus trough level within the physician defined target range within past 6 months and one additional trough level during the screening period within 30% of the physician defined target range.
- Body mass index (BMI) greater than or equal to 19 but less than or equal to 35
- Patients who are taking tacrolimus (generic, Sandoz) or Prograf
Exclusion Criteria:
- Evidence of any acute rejection
- Patients who require dialysis within 6 months prior to study entry
- Recipients of antibodies blood group (ABO) incompatible allograft or positive crossmatch
- Recipients of multiple organ transplants
- Patients who have tested positive for hepatitis B surface antigen (HBsAG) or human immunodeficiency virus (HIV), or who are recipients of organ from donors who are known to be HBsAG or HIV positive. Virology screening at the time of transplant was acceptable unless more recent tests were available.
- History of malignancy, treated or untreated, within the past 2 years with the exception of carcinoma in situ or excised basal cell carcinoma
- Glomerular filtration rate ≤35 ml/min measured by modification of diet in renal disease (MDRD4)
- No anticipated change in the immunosuppressive regimen during patient participation other than that required by the protocol
- Initiation of any medications that could interfere with tacrolimus blood levels, including over the counter medications, herbal supplements, grapefruit or grapefruit juice.
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL)
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are
- women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
- women whose partners have been sterilized by vasectomy or other means
- using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs); periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.
- Patients who are taking a generic tacrolimus product other than tacrolimus (generic, Sandoz).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1 - Branded Tacrolimus / Generic Tacrolimus
In Period 1 (Days 1-14) participants received branded tacrolimus (Prograf) orally twice a day and in Period 2 (Days 15 - 28) participants received generic tacrolimus (Sandoz) orally twice a day.
Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
|
Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
Other Names:
Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
Other Names:
|
Active Comparator: Sequence 2 - Generic Tacrolimus / Branded Tacrolimus
In Period 1 (Days 1 - 14) participants received generic tacrolimus (Sandoz) orally twice a day and in Period 2 (Days 15 - 28) participants received branded tacrolimus (Prograf) orally twice a day.
Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
|
Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
Other Names:
Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Normalized Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12h) at Steady State
Time Frame: Days 14 and 28: Predose and at 0.5, 1, 1.5, 1.75, 2, 3, 4, 8 and 12 hours after dosing.
|
Dose-normalized area under the concentration-time curve from time 0 to 12 hours (AUC0-12h) at steady state after 14 days of treatment with each study drug. Geometric mean and 95% confidence intervals were determined from an analysis of variance (ANOVA) model for the dose-normalized log transformed values with treatment, period and sequence as fixed factors and patients nested within sequences as a random factor. |
Days 14 and 28: Predose and at 0.5, 1, 1.5, 1.75, 2, 3, 4, 8 and 12 hours after dosing.
|
Dose-normalized Maximum Plasma Drug Concentration (Cmax) at Steady State
Time Frame: Days 14 and 28: Predose and at 0.5, 1, 1.5, 1.75, 2, 3, 4, 8 and 12 hours after dosing.
|
Maximum (peak) plasma drug concentration after drug administration at steady state (after 14 days of treatment with each study drug).
Geometric mean and 95% confidence intervals were determined from an analysis of variance (ANOVA) model for the dose-normalized log transformed values with treatment, period and sequence as fixed factors and patients nested within sequences as a random factor.
|
Days 14 and 28: Predose and at 0.5, 1, 1.5, 1.75, 2, 3, 4, 8 and 12 hours after dosing.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intra-patient Variability of Tacrolimus Pharmacokinetic Parameters
Time Frame: Days 7 and 14, and Days 21 and 28.
|
The intra-patient variability of tacrolimus pharmacokinetics of each formulation was evaluated by comparing AUC0-12h, maximum drug concentration (Cmax) and trough drug concentration (C0) at Days 7 and 14, and Days 21 and 28.
Intra-patient variability was assessed by a calculation of the coefficient of variation, by patient, using the repeated measurements within each Period, where the coefficient of variation (%) = standard deviation/mean*100.
|
Days 7 and 14, and Days 21 and 28.
|
Trough Plasma Drug Concentration (C0) at Steady State
Time Frame: Days 14 and 28: predose
|
Trough plasma drug concentration measured prior to drug administration at steady state (after 14 days of treatment with each study drug).
|
Days 14 and 28: predose
|
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
Time Frame: 28 Days
|
An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event was not considered to be related to study drug.
An SAE was an event which: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; required or prolonged inpatient hospitalization; was medically significant, i.e., an event that jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.
|
28 Days
|
Number of Participants With Reported Biopsy Proven Acute Rejection Episodes
Time Frame: 28 Days
|
28 Days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERL080AUS90
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplant
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
Queen Mary University of LondonRecruitingImmunosuppression | Renal Transplant Rejection | Renal Transplant Failure | Renal Transplant InfectionUnited Kingdom
-
PfizerCompletedRenal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft RecipientsUnited States, Australia, Germany, Italy, Spain, Brazil, Argentina
-
Ha Young OhBaxter Healthcare CorporationUnknownAcute Rejection of Renal Transplant | Delayed Function of Renal Transplant | Primary Nonfunction of Renal TransplantKorea, Republic of
-
Alp SenerNot yet recruitingRenal Transplant | Kidney Transplant
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
National Institute of Allergy and Infectious Diseases...University of PittsburghRecruitingKidney Transplant | Renal Transplant RecipientsUnited States
-
Liverpool University Hospitals NHS Foundation TrustKidney Research United KingdomNot yet recruitingFrailty | Kidney Transplant Rejection | Renal Transplant | Diagnosis | Kidney Transplant; Complications | Kidney Transplant | Renal Transplant Failure | Transplant DysfunctionUnited Kingdom
-
Jeffrey Veale, MDOneLegacy FoundationRecruitingTolerance | Renal Transplant Rejection | Kidney TransplantUnited States
-
University of AarhusCompletedRenal Transplant Candidate for Right Kidney | Renal Transplant Candidate for Left KidneyDenmark
Clinical Trials on Generic Tacrolimus
-
University of CincinnatiUniversity of Colorado, Denver; Children's Hospital Medical Center, CincinnatiCompletedLiver Transplant Recipients | Kidney Transplant RecipientsUnited States
-
Veloxis PharmaceuticalsCompletedRenal FailureUnited States
-
Vastra Gotaland RegionCompleted
-
University of Oslo School of PharmacyOslo University HospitalCompleted
-
SandozWithdrawn
-
Astellas Pharma Global Development, Inc.Completed
-
Dr. Amy Latimer-Cheung, PhDCompleted
-
University of PeshawarCompleted
-
University of PeshawarCompleted
-
Unity Health TorontoCanadian Institutes of Health Research (CIHR)Completed